iRhythm Technologies Inc - On May 25, Received Warning Letter From FDA Which Resulted From Inspection Of Co.'s Facility Located In Cypress; Letter Alleges Non-Conformities To Regulations For Medical Devices, Relating To Co's Zio AT System
Portfolio Pulse from Benzinga Newsdesk
iRhythm Technologies received a warning letter from the FDA on May 25, alleging non-conformities to regulations for medical devices related to the company's Zio AT System.
May 30, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
iRhythm Technologies' stock may be negatively impacted by the FDA warning letter regarding non-conformities in its Zio AT System.
The FDA warning letter directly targets iRhythm Technologies' Zio AT System, which may lead to potential regulatory issues and affect the company's reputation. This could result in a negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100